Immune checkpoint inhibitors and targeted therapies, two new class of drugs for treatment of metastatic melanoma, have not been compared in randomized controlled trials (RCT). We quantitatively summarized the evidence and compared immune and targeted therapies in terms of both efficacy and toxicity.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2jXlAUy
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
ACS Nano DOI: 10.1021/acsnano.7b04100 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2h0ZFyU via...
-
Molecules, Vol. 24, Pages 2837: Bioavailability and Bioactivity of Encapsulated Phenolics and Carotenoids Isolated from Red Pepper Waste Mol...
-
Whether to wear a pollution filter Development of air quality forecasting system in Macedonia, based on WRF-Chem model Abstract Urban air qu...
-
Abstract Background Henoch–Schönlein purpura is the most common vasculitis in children. Its long-term prognosis depends on renal involve...
-
Denotation as Complex and Chronologically Extended: anvitābhidhāna in Śālikanātha's Vākyārthamātṛkā - I Abstract The two theories of ve...
-
UM-Chor1: establishment and characterization of the first validated clival chordoma cell line. J Neurosurg. 2017 Apr 21;:1-9 Authors:...
-
Publication date: Available online 10 May 2017 Source: Journal of Dairy Science Author(s): R.E. Vibart, M. Tavendale, D. Otter, B.H. Schw...
-
Abstract Cerebral and systemic organ microvascular pathologies coexist with human Alzheimer’s disease (AD) neuropathology. In this study, w...
-
Tetracycline Repressors (TetRs) modulate multi-drug efflux pathways in several pathogenic bacteria. In Streptomyces, they additionally regul...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου